Atorfit

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Atorfit

What is Atorfit? (Overview)

Atorfit is a specific trade name for a prescription drug manufactured by Ajanta Pharma Ltd., functioning as a potent lipid-lowering agent whose primary purpose is to help maintain a healthy cholesterol balance in the blood.

Property Description
Active ingredient Atorvastatin
Form Tablet (oral)
Pharmacological class HMG-CoA Reductase Inhibitor (Statin)
Common use Managing high blood lipid (fat) levels
Origin Synthetic compound

Atorfit: Identity and Classification as a Statin

The active ingredient is Atorvastatin, which is classified as a synthetic compound, chemically identified as a dihydroxy monocarboxylic acid. Atorvastatin is formally classified as an HMG-CoA reductase inhibitor, the precise term for the group of medicines known as statins.

A key differentiating factor of Atorvastatin is its long half-life, which supports effective, consistent cholesterol synthesis inhibition.

Composition and General Purpose

The Atorfit product is a single-entity medicine composed of Atorvastatin (usually as the calcium salt) formulated as a tablet for oral administration. Its general role is to function as a lipid-lowering agent by systematically reducing the concentration of certain fatty substances in the bloodstream.

Specifically, it works to lower low-density lipoprotein cholesterol (LDL-C), or "bad cholesterol," and triglycerides. By managing these specific lipids, the drug aims to support overall cardiovascular health and addresses cardiovascular risk factors.

Regulatory References

  1. MedlinePlus, NIH
  2. StatPearls, NIH
  3. DrugBank, NIH

What side effects are possible with Atorfit?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Atorfit (Atorvastatin), organized according to regulatory classification systems such as System-Organ Classes (SOCs) and frequency.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency as defined in regulatory documents. Common (ge 1 in 100 patients) reactions include nasopharyngitis, headache, and disturbances affecting the gastrointestinal and musculoskeletal systems, such as myalgia (muscle pain), arthralgia, constipation, flatulence, and nausea. Increases in liver enzyme levels (serum transaminases) are also classified as common. Uncommon (ge 1 in 1,000 patients) reactions may involve dizziness, vomiting, abdominal pain, rash, and fatigue. Rare (ge 1 in 10,000 patients) events include serious conditions like rhabdomyolysis (severe muscle breakdown) and hepatitis.


Serious Adverse Reactions and Safety Constraints

Official labeling emphasizes certain serious adverse reactions. Rhabdomyolysis and potentially life-threatening liver injury (hepatotoxicity) are explicitly documented as serious risks associated with this medicine. The drug is formally contraindicated by government health authorities in patients with active liver disease or unexplained persistent elevations of serum transaminases. Furthermore, Atorfit is constrained from use during pregnancy and breastfeeding. Safety notes also indicate that the risk of musculoskeletal adverse reactions, including rhabdomyolysis, may be increased in older adults (ge 65 years). Liver enzyme elevations are often documented as being more frequent at the start of treatment.

Overdose and Emergency Response

Overdose and when to seek help: Official Regulatory Information

The official regulatory documentation for Atorvastatin (the active ingredient in Atorfit) indicates that no specific clinical symptoms or signs are uniquely documented to characterize an acute overdose. Consequently, the regulatory focus for overdose management centers on the potential for severe, life-threatening complications related to high-dose exposure.

The most serious concern is the potential for rhabdomyolysis and subsequent acute renal failure. In all cases of suspected overdose, immediate medical attention must be sought.

This requirement is absolute because there is no specific antidote known for Atorvastatin. Official regulatory guidance mandates that management must be strictly symptomatic and supportive within a clinical setting. Monitoring of muscle-related enzyme levels, such as creatine phosphokinase (CPK), and renal function is typically warranted.

Furthermore, because the active ingredient is extensively bound to plasma proteins, regulatory statements advise that procedures such as haemodialysis are not expected to be effective in significantly enhancing the drug's clearance from the body. Consequently, a high degree of observation and supportive intervention is the required regulatory approach.

Therapeutic Uses of Atorfit

What Atorfit treats: Main Uses and Benefits

Atorfit is commonly used for managing specific chronic conditions related to blood lipid abnormalities, contributing to support for long-term cardiovascular health. The therapy generally plays a role in managing biochemical risk factors to assist with the prevention of serious health outcomes.

Atorfit (Atorvastatin) is used to address high concentrations of low-density lipoprotein cholesterol (LDL-C) and triglycerides in the blood. The medication is relevant for managing Primary Hyperlipidemia, Mixed Dyslipidemia, and specific inherited conditions such as Familial Hypercholesterolemia.

Primary Therapeutic Focus

The use of Atorfit plays a role in managing factors associated with cardiovascular event risk, serving as a long-term supportive strategy for patients at high risk, including those with multiple risk factors or established Coronary Heart Disease. Using Atorfit in this context helps support the management of the cardiovascular strain associated with these intense genetic and chronic risk factors.

“The therapy is relevant for addressing the symptomatic domain of lipid imbalances, which may assist with maintaining functional stability.”


Quick Fact: Relief for Elevated Blood Lipids Atorfit is commonly used to help with conditions marked by chronic elevated LDL-C and triglycerides, supporting the patient during symptomatic periods of lipid abnormality.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

The eligibility profile for Atorfit (atorvastatin) is determined by governmental regulatory bodies (such as the FDA and EMA) and is primarily defined by the patient's liver health, reproductive status, and age.

Populations For Whom Use Is Contraindicated:

  • Active Liver Disease: Use is strictly prohibited in patients with active liver disease, including acute liver failure or decompensated cirrhosis, or those with unexplained persistent elevations of hepatic transaminases.
  • Reproductive Status: The medicine is contraindicated during pregnancy and lactation (breastfeeding). Use is also generally advised against for women of child-bearing potential who are not using effective contraception.
  • Hypersensitivity: Patients with known hypersensitivity to atorvastatin or any component of the medication must not use it.

Age-Related Eligibility and Limitations:

Age Group Eligibility Status (Regulatory Basis)
Adults (18+ years) Approved for standard labeled use.
Pediatric (10–17 years) Approved only for specific conditions (Heterozygous and Homozygous Familial Hypercholesterolemia).
Children (< 10 years) Use is generally not established due to insufficient safety and efficacy data.
Older Adults (Geriatric) Use is permitted, but advanced age is a noted risk factor for myopathy, requiring caution.

Conditional Use and Risk Factors:

Certain pre-disposing conditions require caution and assessment before and during treatment. These include a history of substantial alcohol consumption, uncontrolled hypothyroidism, renal impairment, and a personal or familial history of hereditary muscular disorders. While renal impairment does not necessitate a dose adjustment, it is listed as a factor that may increase the risk of muscle problems.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile of Atorfit (Atorvastatin) establishes interactions primarily categorized by their effect on systemic concentration and the resulting risk of skeletal muscle effects.

Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Potent and moderate inhibitors of CYP3A4; inhibitors of OATP1B1 transporters; fibric acid derivatives; and high-dose niacin (ge1 g/day).
Specific interacting medicines (if explicitly listed) Contraindicated: Cyclosporine, Tipranavir plus Ritonavir, Glecaprevir plus Pibrentasvir. Other Key Interactions: Clarithromycin, Itraconazole, Rifampin, and Colchicine.
Mechanistic basis of interactions (only if stated in label) Inhibition of Cytochrome P450 3A4 and hepatic uptake transporters leads to markedly increased Atorvastatin plasma concentrations.
Timing-based interaction rules (if applicable) Co-administration with Rifampin requires simultaneous dosing to avoid a documented reduction in Atorvastatin plasma concentrations.
Population-specific interaction notes (if applicable) Hepatic Impairment and advanced age are documented as risk factors that may compound the severity of exposure-increasing interactions.
Interaction-related restrictions Formal restrictions exist for combining Atorfit with large quantities of grapefruit juice (>1.2 liters/day) due to potential plasma concentration increases.

Interaction Classifications (High-Level)

Classification Official Regulatory Statement
Interaction severity classification (as defined in official documents) Combinations are classified as Contraindicated or require specific Dose Restrictions (e.g., Clarithromycin le20 mg daily) to mitigate the risk of myopathy/rhabdomyolysis.
Regulatory basis (EMA / FDA / etc.) Interaction data is formalized within the FDA Prescribing Information and EMA Summary of Product Characteristics (SmPC).

Resulting interaction structure

Official interaction statements:

  • Co-administration with potent CYP3A4 and transporter inhibitors is documented to result in markedly increased systemic exposure to Atorvastatin.
  • The combination with Fibric Acid Derivatives or lipid-modifying doses of Niacin (ge1 g/day) is associated with an increased risk of adverse skeletal muscle effects.
  • The regulatory label lists specific combinations, including Cyclosporine and certain HIV/HCV Protease Inhibitors, as contraindicated or requiring dose restrictions.

Connection to the overall interaction profile (2–4 sentences): Government regulatory documents define Atorfit's interaction structure primarily through two pathways: the pharmacokinetic increase in plasma exposure via inhibition of the CYP3A4 enzyme and hepatic uptake transporters, and the pharmacodynamic reinforcement of the risk for myopathy when combined with other lipid-modifying agents. These documented patterns establish specific, required dose restrictions and contraindicated combinations to manage the elevated risk of skeletal muscle adverse events.

Mechanism of Action

Atorfit is a pharmacologic agent containing the active compound atorvastatin, which functions as a selective, competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme is the rate-limiting step in the mevalonate pathway, the primary route for endogenous cholesterol biosynthesis, primarily localized in the hepatic tissue.

The mechanism of action commences with the reversible binding of atorvastatin to the active site of HMG-CoA reductase. This molecular interaction prevents the conversion of HMG-CoA to mevalonate, thereby reducing the intracellular concentration of sterols, including cholesterol, within the liver cells. This decline in hepatic cholesterol triggers a compensatory up-regulation of high-affinity low-density lipoprotein (LDL) receptors on the hepatocyte cell membrane.

The increase in hepatic LDL receptors facilitates an enhanced clearance and subsequent catabolism of circulating LDL and very-low-density lipoprotein (VLDL) remnants from the plasma. The overall physiological consequence is a modulation of systemic lipoprotein concentrations, resulting from the initial intracellular enzymatic inhibition and the subsequent receptor-mediated clearance cascade.

Dosage and Administration Information

Instruction Map: How to use Atorfit — Administration Guidelines

Administration Scope Detail
Route of administration: Oral
Dosing schedule: Adult patients are typically started at 10 mg or 20 mg once daily. The standardized dosage range is 10 mg to 80 mg once daily. The maximum recommended daily dose is 80 mg.
Timing in relation to meals (if applicable): The tablet may be administered as a single dose at any time of the day, with or without food.
Preparation requirements (if applicable): The oral suspension formulation must be shaken well and administered on an empty stomach (one hour before or two hours after a meal).
Age-group administration rules: For pediatric patients (ge 10 years) with Heterozygous Familial Hypercholesterolemia, the maximum recommended daily dose is 20 mg. No general dosage adjustment is necessary for patients with renal impairment.
Missed-dose rules: If a scheduled dose is missed by more than 12 hours, the missed dose should be skipped.
Special procedural conditions: Concomitant intake of large quantities of grapefruit juice is not recommended. Strict dose limits (e.g., maximum 20 mg daily) are applied when co-administered with specific interacting medications.

Instruction Classifications (High-Level)

Classification Detail
Administration method type: Oral (tablet or suspension)
Frequency pattern: Daily (once per day)
Use-context constraints: Dose-limiting interactions; time-dependent titration schedule; dietary restrictions.

Resulting procedural structure

Step sequence:

  • Take the prescribed dose once daily, ensuring the tablet form is taken with flexibility regarding meals and time of day.
  • Dose changes, known as titration, must be assessed only after a minimum of four weeks has elapsed from the previous dose adjustment.
  • Adhere to strict dose maximums when co-administered with select interacting medications.

Connection to the overall use protocol (2–4 sentences): The standard administration involves a once-daily oral dose within a defined 10 mg to 80 mg range, establishing a consistent regimen. The structured use of the medicine is supported by a minimum four-week interval for any dose adjustment, which allows for therapeutic response assessment. The instructions specify that the tablet form offers flexibility regarding food intake, while simultaneously placing limits on consumption of large quantities of grapefruit juice.

Recent Clinical Evidence

Research evidence / Overview of Studies for Atorfit

The research evidence for Atorfit (Atorvastatin) is drawn from clinical evaluations, primarily focusing on what studies measured regarding blood lipid biomarkers and the long-term observation of major cardiovascular outcomes. The evidence is derived from official sources, including large-scale randomized controlled trials (RCTs), systematic reviews, and long-term observational data.


Evidence for Use in Preventing Cardiovascular Events

Research examining the use of Atorvastatin in this context included several large, international Randomized Controlled Trials (RCTs). The primary goal of these trials was to monitor the occurrence of Major Adverse Cardiovascular Events (MACE)—serious, disruptive episodes such as a non-fatal heart attack, stroke, or the need for coronary artery procedures. The findings describe patterns observed in the studies related to the frequency of MACE and all-cause mortality over the observation periods, typically spanning several years.

What remains uncertain is the durability of these observations over very long periods. Follow-up durations were limited in the initial primary trials, with most evidence focusing on periods of up to six years; there is limited information for long-term outcomes extending over ten years. Comparative evidence is lacking for direct head-to-head trials against all other potent statins using MACE as the primary, long-term endpoint.


Evidence for Use in Managing High Blood Lipids (Dyslipidemia)

Research for managing high blood lipid levels was studied in numerous Randomized Controlled Trials. Studies report measurements showing changes in the observed LDL-C concentrations during the study period. The research provides insight into short-term changes in lipid levels, but these reported outcomes are largely based on measured values from blood tests rather than on direct, long-term clinical events.

It is not yet clear whether the observed short-term lipid changes translate directly to specific, long-term cardiovascular event reduction in patients with low overall risk, as research often relies on these measured blood test values. Evidence quality varies across studies concerning the measured effects on all different types of lipids.


What Remains Uncertain in the Research Record

The research highlights what is known and what is still uncertain. The primary limitations include that follow-up durations were limited in key trials when compared to the long-term nature of cardiovascular disease progression. Comparative evidence is lacking for some head-to-head comparisons against other cholesterol-lowering agents using the most serious clinical outcomes as the primary endpoint. Furthermore, certainty remains low regarding the long-term outcomes in pediatric cohorts, as research is ongoing and data are still emerging.

Key Studies & References Meta-analysis of the effect of atorvastatin on serum lipid levels

Frequently Asked Questions (FAQ)

Common questions about Atorfit (FAQ)


Q: Do you have to take Atorfit forever once you start it?

Atorfit is typically described in official documents as a long-term treatment used to manage chronic conditions like high cholesterol. Studies reviewed by regulatory bodies indicate that stopping therapy may be associated with a potential increase in cardiovascular risk. Any decision regarding the duration of therapy is a personalized assessment that is made by a healthcare professional.


Q: Does Atorfit cause muscle pain or cramping in the legs?

Yes, muscle pain, known formally as myalgia, is documented in official regulatory information as a common side effect. A more severe, though rare, muscle condition called rhabdomyolysis is also noted in government safety warnings. Patients are encouraged to discuss any unexpected or persistent muscle pain with a healthcare provider, as noted in patient safety information.


Q: Is it okay to drink coffee or tea while taking Atorfit?

Official regulatory documents defining the use of Atorfit do not list any specific restrictions or adverse interactions with the consumption of coffee or tea. The primary dietary caution noted in the official guidance relates only to avoiding large quantities of grapefruit juice.


Q: Can Atorfit interact with common pain relievers like ibuprofen?

Formal regulatory documents do not list common, over-the-counter Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen as specific interacting medicines that require a dose adjustment for Atorfit. The official interaction profile focuses on medicines that significantly affect liver enzymes or specific transport proteins.


Q: Is there a link between Atorfit and problems with memory or confusion?

Government health authorities have noted that cognitive impairment, such as memory loss, forgetfulness, and confusion, has been reported in post-marketing experience with statins. These reports are generally described as not serious and are often noted to be reversible upon stopping the medicine.


Q: Can older adults safely use Atorfit?

Yes, Atorfit is approved for use in older adults. Official documents, however, state that advanced age (generally defined as 65 years and older) is listed as a risk factor for muscle-related side effects. The official documentation notes that closer monitoring may be considered.


Q: Does taking Atorfit affect the risk of developing diabetes?

Official safety labels from government health authorities state that statins have been found to cause small increases in blood sugar (glucose) levels and HbA1c levels. This finding may be associated with a small increased risk of developing new-onset diabetes.


Q: Is Atorfit used for other conditions besides lowering cholesterol?

Yes. While Atorfit is primarily known for managing high blood lipid levels (fats), official documentation describes its approved use for the reduction of cardiovascular event risk, such as a heart attack or stroke, in specific high-risk patient groups, including those with or without existing high cholesterol.


Q: Can Atorfit be prescribed for children or teenagers?

Official regulatory documents state that Atorfit is approved for use in pediatric patients aged 10 to 17 years only for specific inherited conditions, such as Familial Hypercholesterolemia. Use in children younger than 10 years is generally not established due to insufficient safety and efficacy data.


Q: What should a patient do if they think they are experiencing a side effect from Atorfit?

Government safety and patient guidelines emphasize that any patient who believes they are experiencing a side effect should promptly contact their healthcare provider. Immediate medical attention is officially noted as necessary if severe symptoms occur, such as signs of serious liver damage or severe muscle pain accompanied by fever.


Q: Does Atorfit interact with supplements like fish oil or multivitamins?

Specific, direct interactions with common supplements like fish oil or multivitamins are not typically noted in the regulatory labels for Atorfit. Official documentation indicates the importance of informing a healthcare professional about all medications, supplements, and herbal products being used.


Q: What is the difference between Atorfit and other statin medications?

Atorfit's active ingredient, atorvastatin, is classified in pharmacological literature as a lipophilic (fat-soluble) statin with a relatively long half-life (duration of inhibitory activity is 20 to 30 hours). This feature supports the official once-daily dosing at any time of day, distinguishing it from some other statins.


Q: Does Atorfit make you feel tired or lacking energy?

Yes, fatigue is listed in regulatory documents as an uncommon side effect, meaning it has been reported in at least 1 in 1,000 patients in clinical studies. Asthenia (lack or loss of strength) is also noted as an uncommon reaction.


Q: Is Atorfit known to cause changes in mood or feelings of depression?

Mood changes, including depression, are not listed as common adverse reactions in the main adult regulatory documents based on clinical trials. However, depression has been noted in post-marketing reports for the drug class.


Q: Can a person stop taking Atorfit once their cholesterol levels improve?

Official documents describe Atorfit as a crucial part of a long-term strategy for managing cardiovascular risk. Studies indicate that discontinuing therapy, even after achieving lipid targets, may be associated with a potential increase in cardiovascular risk. Any decision to stop or interrupt treatment is a medical determination that is made by a healthcare professional.


Q: Are there specific warnings about Atorfit and pregnancy or breastfeeding?

Yes, the regulatory profile of Atorfit includes strong warnings. Its use during both pregnancy and lactation (breastfeeding) is formally classified as contraindicated by government health authorities, meaning it is strictly prohibited.


Q: Is Atorfit a drug that can cause weight gain or loss?

Weight gain is noted in post-marketing reports for the drug class. However, neither weight gain nor weight loss is listed as a common or specific adverse reaction in the main regulatory documents based on clinical trials.


Q: Can Atorfit be taken with blood pressure medication?

Yes, Atorfit is often used alongside certain blood pressure medications. Official regulatory documents note that some classes, like Calcium Channel Blockers, may potentially increase the concentration of Atorfit in the blood. This increased exposure may be noted as requiring specific dose adjustments or closer monitoring.


Q: Is the potential for severe side effects common with Atorfit?

The most severe side effects officially documented for Atorfit, such as rhabdomyolysis (severe muscle breakdown) and severe liver injury, are classified as rare events. This means they are reported in fewer than 1 in 10,000 patients. The most common side effects are generally classified as mild to moderate.


Q: Do people ever develop an allergy to Atorfit?

Yes, the official regulatory profile includes Hypersensitivity (a type of allergic reaction) as a contraindication. Patients with a known allergy to the medicine or any component must not take it. Rare cases of severe allergic reactions have been reported.


Q: Does Atorfit affect hormone levels or sexual function?

Official regulatory labels do not list changes in hormone levels or sexual dysfunction as common or definitive side effects. However, issues like loss of sexual ability/drive have been noted in post-marketing reports for the drug class.


Q: Are there any specific risks for people with a history of stroke or heart attack?

While Atorfit is often used in these patients for risk reduction, a specific warning exists. For patients who have recently experienced a non-cardioembolic stroke or TIA (transient ischemic attack), high-dose atorvastatin may be associated with an increased risk of hemorrhagic stroke, according to official labeling.


Q: Can taking Atorfit affect vision or eye health?

Yes, vision blurred is listed in regulatory documents as an adverse reaction reported in clinical trials. Other issues, such as visual impairment and vision field defects, are also noted in documentation as rare side effects.


Q: Is Atorfit an over-the-counter medicine in any country?

Atorfit, which contains the active ingredient atorvastatin, is classified as a prescription-only medicine by government health authorities worldwide. It is not available over-the-counter.


Q: Does Atorfit interact with herbal remedies like St. John's Wort?

Yes, official sources note that the herbal supplement St. John's Wort may reduce the concentration and effectiveness of Atorfit in the blood. This documented interaction is noted as possibly requiring monitoring or a dose adjustment.


Q: Does Atorfit need to be stored in a special way?

Yes, official regulatory instructions require the tablets to be stored at a controlled room temperature (typically 20 C to 25 C). The medicine must be kept in its original, tightly closed container, and stored away from excess heat and moisture.


Q: Can Atorfit be taken with antacids or acid-reducing medications?

Official drug labeling notes that taking Atorfit with an antacid that contains magnesium and aluminum hydroxide can reduce the concentration of Atorfit in the blood. Regulatory documents indicate the antacid should be taken at a different time than the Atorfit dose.

How should Atorfit be stored and disposed of?

Official Storage Requirements

Atorfit (atorvastatin) tablets must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F), and must not exceed 30 C. To protect stability, the medicine should be kept in its original, tightly closed container and stored away from excess heat and moisture.

Child Safety and Disposal

It is a mandatory regulatory requirement to keep Atorfit out of the sight and reach of children.

Expired or unused tablets must not be thrown away in the household trash or disposed of via wastewater (e.g., flushed down the toilet or sink). Instead, the official instructions require patients to ask a pharmacist or follow local pharmaceutical waste guidelines for appropriate disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Atorfit found in:

A-Z Index: